Completed PHASE3 INTERVENTIONAL 1-arm NCT00689338

Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study (ICE)

Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole Or Fluconazole Therapy, For Treatment Of Documented Candidemia/Invasive Candidiasis In Intensive Care Unit Patient Populations

Sponsor: Pfizer

Conditions Invasive Candidiasis

Interventions Anidulafungin Fluconazole Voriconazole

Updated 8 times since 2017 Last updated: May 25, 2011 Started: Jul 31, 2008 Primary completion: May 31, 2010 Completion: May 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Invasive Candidiasis, this trial is completed. The trial is conducted by Pfizer and has accumulated 8 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jul 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amiens, France , Ankara, Turkey (Türkiye) , Berlin, Germany , Bordeaux, France , Bratislava, Slovakia , Brno, Czechia , Brussels, Belgium , Bucharest, Romania , Budapest, Hungary , Clichy, France and 42 more locations